Global Oral Anticoagulants Market Share Is Likely To Reach At A CAGR Value Of Around 9.6% By 2028

23-Sep-2022 | Facts and Factors

According to Facts and Factors, the global oral anticoagulants market size was worth around USD 18 billion in 2021 and is predicted to grow to around USD 34.1 billion by 2028 with a compound annual growth rate (CAGR) of roughly 9.6% between 2022 and 2028.

Oral anticoagulant is a drug that is used to prevent blood clotting by adding a few amounts of oral anticoagulant into the blood. The blood has numerous clotting functions and the synthesis of these functions is suppressed by anticoagulants. Anticoagulant medication is intended to stop blood clots from spreading throughout the bloodstream, forming in the arteries or veins, or in any other way. Doctors frequently employ oral anticoagulants, commonly referred to as blood thinners, to lessen or eliminate the coagulant of the blood during the blood clotting phase. Deep vein thrombosis, atrial fibrillation, myocardial infarction, stroke, pulmonary embolism, and other illnesses are among those where the risk of blood clotting is comparatively high. During the projection period, the worldwide anticoagulant market experienced tremendous growth.

Browse the full “Oral Anticoagulants Market Size, Share, Growth Analysis Report By Product (Warfarin and Novel Oral Anticoagulant), By Disease Indication (Atrial Fibrillation (AF)/ Stroke Prevention and Deep Vein Thrombosis/ Pulmonary Embolism), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/oral-anticoagulants-market

The prevalence of venous thromboembolism (VTE) and other cardiovascular diseases is on the rise globally, and this has an impact on the global oral anticoagulant market growth. The main drivers of market expansion are the demand for innovative oral anticoagulants (NOACs) and the growing concern over these drugs in emerging nations. The rise in the older population and those aged 65 and over, the need for novel therapies, and the heightened unmet demands all contribute to the market's expansion. During the projected time, the market expansion will be hampered by the lack of NOAC antidotes and the NOACs' higher or more expensive costs.

The global oral anticoagulants market is segmented based on product, disease indication, distribution channel, and region.

The global market is divided into two segments based on the product: warfarin and new oral anticoagulants. The market share leader in 2021 was the warfarin segment, and it is anticipated that it will continue to dominate during the projected period. An oral anticoagulant called warfarin is frequently used to treat and prevent blood clots. There are many FDA-approved and off-label clinical uses for warfarin, including the prevention and treatment of venous thrombosis and arising pulmonary embolisms, the prevention and treatment of thromboembolic complications from atrial fibrillation or cardiac valve replacement, the reduction of the risk of death, recurrent myocardial infarction, thromboembolic events (such as stroke, systemic embolization) after myocardial infarction, and secondary prevention of recurrent stroke, and transient ischemic attacks. Besides, Novel oral anticoagulants are anticipated to experience the highest CAGR growth during the projection period. The novel oral anticoagulants are apixaban, rivaroxaban, edoxaban, and dabigatran etexilate. In comparison to vitamin K antagonists, these anticoagulants have important pharmacologic advantages, such as functional activity balancing and predictable pharmacokinetics, which eliminate the need for general coagulation monitoring, resulting in the segment's growth.

Hospital pharmacies, retail pharmacies, and online pharmacies are the three categories into which the global market is split based on distribution channels. The market share leader in 2021 was the segment of hospital pharmacies, and this trend is anticipated throughout the forecast period. Hospital pharmacies have several benefits, including easier pharmaceutical access. Since these departments have a more advanced infrastructure and medical staff, a major proportion of CVD patients visit hospital outpatient departments (OPDs) for treatment and pharmaceutical prescriptions. More patients will choose to obtain their treatments at hospitals to receive high-quality care, which will result in a significant increase in the sales of anticoagulants across all in-house pharmacies.

Based on geography, the global oral anticoagulants market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Europe is expected to grow at the highest CAGR during the forecast period. The growth in the region is attributed to the growing pool of a geriatric population. For instance, according to the World Bank, Germany’s share of the population aged 65 years and above stood at 21.98% in 2021. This factor has positively influenced the demand for anticoagulants. The demand for improvised and non-invasive treatments is rising among the regional geriatric population. Furthermore, the region is also witnessing a healthy rise in new drug agreements between governments and healthcare organizations. For instance, in November 2021, NHS England signed new agreements to scale up the production of direct oral anticoagulants (DOACs). These contracts would benefit more than 610,000 patients in the country over the next 3 years.

Report Scope

The global oral anticoagulants market is dominated by players like Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Abbott Laboratories, Aspen Holdings, Sanofi, Pfizer, Inc, Alexion Pharmaceuticals Inc., Leo Pharma AS, and Dr. Reddy’s Laboratories, among others.

Recent Development:

In December 2020, Natco Pharma launched an anti-blood clot medication, Rivaroxaban, in India. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. The medication is currently sold by Bayer under the brand name Xarelto, in the Indian market.

The global oral anticoagulants market is segmented as follows:

By Product

• Warfarin
• Novel Oral Anticoagulant

By Disease Indication

• Atrial Fibrillation (AF)/ Stroke Prevention
• Deep Vein Thrombosis/ Pulmonary Embolism

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com